| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | -38.65% | Morgan Stanley | $3 → $1 | Upgrades | Underweight → Equal-Weight |
| 11/03/2023 | 881.6% | BMO Capital | $18 → $16 | Maintains | Outperform |
| 11/02/2023 | 329.45% | HC Wainwright & Co. | $17 → $7 | Maintains | Buy |
| 10/09/2023 | 22.7% | B of A Securities | $5 → $2 | Maintains | Neutral |
| 08/09/2023 | 942.94% | HC Wainwright & Co. | $25 → $17 | Maintains | Buy |
| 05/30/2023 | 513.5% | Evercore ISI Group | $20 → $10 | Maintains | Outperform |
| 05/12/2023 | 84.05% | Morgan Stanley | $5 → $3 | Maintains | Underweight |
| 05/08/2023 | 1433.74% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 03/28/2023 | 206.75% | B of A Securities | $11 → $5 | Maintains | Neutral |
| 02/27/2023 | 206.75% | Morgan Stanley | $6 → $5 | Maintains | Underweight |
| 02/24/2023 | 2047.24% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 02/24/2023 | 206.75% | JP Morgan | $15 → $5 | Downgrades | Neutral → Underweight |
| 01/03/2023 | 452.15% | Wells Fargo | $11 → $9 | Maintains | Equal-Weight |
| 11/08/2022 | 574.85% | Wells Fargo | $12 → $11 | Maintains | Equal-Weight |
| 11/04/2022 | 820.25% | JP Morgan | $22 → $15 | Downgrades | Overweight → Neutral |
| 10/11/2022 | 268.1% | Morgan Stanley | → $6 | Initiates Coverage On | → Underweight |
| 05/09/2022 | 2047.24% | HC Wainwright & Co. | $63 → $35 | Maintains | Buy |
| 04/28/2022 | 513.5% | Credit Suisse | → $10 | Initiates Coverage On | → Underperform |
| 04/18/2022 | 1495.09% | UBS | $64 → $26 | Maintains | Buy |
| 04/11/2022 | 1126.99% | BMO Capital | $57 → $20 | Maintains | Outperform |
| 03/10/2022 | 2538.04% | JP Morgan | → $43 | Initiates Coverage On | → Overweight |
| 02/10/2022 | 1433.74% | Wells Fargo | → $25 | Initiates Coverage On | → Equal-Weight |
| 11/23/2021 | 3212.88% | B of A Securities | → $54 | Initiates Coverage On | → Buy |
| 10/14/2021 | 4010.43% | SVB Leerink | → $67 | Initiates Coverage On | → Outperform |
| 09/30/2021 | 2660.74% | Stifel | → $45 | Initiates Coverage On | → Hold |
| 06/24/2021 | 3212.88% | Brookline Capital | → $54 | Initiates Coverage On | → Buy |
| 06/04/2021 | 3765.03% | HC Wainwright & Co. | → $63 | Initiates Coverage On | → Buy |
| 03/31/2021 | 3274.23% | BMO Capital | → $55 | Initiates Coverage On | → Outperform |
| 10/27/2020 | 1924.54% | BMO Capital | → $33 | Initiates Coverage On | → Outperform |
What is the target price for C4 Therapeutics (CCCC)?
The latest price target for C4 Therapeutics (NASDAQ: CCCC) was reported by Morgan Stanley on November 6, 2023. The analyst firm set a price target for $1.00 expecting CCCC to fall to within 12 months (a possible -38.65% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for C4 Therapeutics (CCCC)?
The latest analyst rating for C4 Therapeutics (NASDAQ: CCCC) was provided by Morgan Stanley, and C4 Therapeutics upgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for C4 Therapeutics (CCCC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating C4 Therapeutics (CCCC) correct?
While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a upgraded with a price target of $3.00 to $1.00. The current price C4 Therapeutics (CCCC) is trading at is $1.63, which is out of the analyst's predicted range.